Roche Holding AG RO.SW SIX · Healthcare · Switzerland
CHF 408.40 -0.63% -CHF 2.60
Summary
68 / 100 · Bulios Score
What speaks for it
- Out of every 100 CHF of revenue, 20 CHF is left as net profit.
- It earns 21 CHF a year on every 100 CHF of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 2.2% a year over the last 3 years.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 26.4 CHF for 1 CHF of yearly profit. Over the last five years it was 22.7 CHF on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 1.1% a year over 5 years. Over the last 3 years it fell by 2.2% a year. For the next fiscal year analysts expect revenue to grow by 3.3%. Earnings per share grew by 1.4% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CHF of revenue goes
- Cost of sales 27 CHF
- Research and development 23 CHF
- Sales and administration 19 CHF
- Taxes and other 12 CHF
- Net profit 20 CHF
Net profit, industry median (Drug Manufacturers - General) 15 CHF
Out of every 100 CHF of revenue, 20 CHF is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 2.64%
- Paid out of profit
- 70%
You receive CHF 10.80 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 5
- Sell 1
No analyst has published a price target.
40% of the analysts recommend buying.
Analysts in detail